Skip to main content
Signal8

GILEAD SCIENCES, INC. (GILD)

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Drug Manufacturers - General

Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

NASDAQ:GILDHealthcare
+1.29%$169.75
Mkt Cap$210.54B
EV-
Float1.24B
O/S1.24B
VOL3.16M sh
$ Vol$537.18M
RVOL0.50×
Inst Own86.4%
SI1.7%
Net Cash/Sh-
Div Yield1.91%
Dilution
Gilead Sciences, Inc. logoNASDAQ:GILD$169.75+1.29%
Short interest (FINRA)
1.7%
Oct 30 (18d)

Float 1.24B · Polygon free float · Nov 2, 2026

21.3M
Oct 30 (18d)prev 20.3M▲ 4.9%
3.18
Oct 30 (18d)prev 3.72▼ 14.5%
Borrow (IBKR)

The cost to borrow GILD shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
38.1%
Nov 16 (1d)prev 39.8%▼ 1.7 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

425
Oct 26 (22d)prev 5.9K▼ 92.8%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202621.3M sh
Oct 15, 202620.3M sh
Sep 30, 202621.8M sh
Sep 15, 202618.3M sh
Aug 31, 202623.0M sh
Latest fails to deliver
DateShares failed
Oct 26, 2026425 sh
Oct 16, 20265.9K sh
Oct 9, 202681.4K sh
Oct 8, 2026360 sh
Sep 15, 20262.0K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202638.1%
Nov 13, 202639.8%
Nov 12, 202646.2%
Nov 11, 202638.4%
Nov 10, 202653.4%
90-session median 39.6%mean 39.0%range 13.0–61.1%

130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for GILD: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 21,271,970 GILD shares were sold short (1.72% of a 1.24B-share float, 3.18 days to cover).